Through a $75 million investment over at least five years, the American Heart Association and Verily, with support from AstraZeneca, are embarking on a groundbreaking research enterprise focused on preventing or reversing coronary heart disease and, ultimately, improving and restoring cardiovascular health. This marks the start of a bold and new chapter as the largest one-time investment in a team with a focus to end coronary heart disease.$75 MILLION + substantial resources and support from all three.
See what people are Saying
"The best idea should triumph. It could be a teenager in Wisconsin who has a brilliant idea."
- Andy Conrad, CEO, Verily
"We trust in the potential of ideas and will pursue them, alone and with others, until we have transformed the treatment of disease."
- Pascal Soriot, CEO, AstraZeneca
"We intend to change the way cardiovascular research is conducted."
- Nancy Brown, CEO, AHA